

Mediterranean School of Oncology (MSO)

Course on:

Highlights in the management of breast cancer

Roma, 10 maggio 2013

Director: Clara Natoli (Chieti)

10.00 - 13.00 - Early disease

Current state of breast cancer classification (*M. Mottolese, Roma*)

B SERIE DI RELAZIONI SU TEMA PREORDINATO

Molecular tools for decision making in adjuvant therapy (*E. Ricevuto, L'Aquila*)

B SERIE DI RELAZIONI SU TEMA PREORDINATO

Current status of adjuvant HER-2 targeting therapy (*V. Guarneri, Modena*)

B SERIE DI RELAZIONI SU TEMA PREORDINATO

13.00 - 14.00 LUNCH

14.00 - 16.30 - Locally advanced and metastatic disease

Overcoming treatment resistance in HER2-positive breast cancer (*F. Puglisi, Udine*)

B SERIE DI RELAZIONI SU TEMA PREORDINATO

Endocrine resistance: molecular pathways and rational development of targeted therapies (*G. Arpino, Napoli*)

B SERIE DI RELAZIONI SU TEMA PREORDINATO

Nanoparticles encapsulated drugs (*A. Fabi, Roma*)

B SERIE DI RELAZIONI SU TEMA PREORDINATO

Eribulin mesylate (E7389): review of efficacy and tolerability (*J. Foglietta, Perugia*)

B SERIE DI RELAZIONI SU TEMA PREORDINATO

How to improve the outcome of TNBC (*C. Bighin, Genova*)

B SERIE DI RELAZIONI SU TEMA PREORDINATO

Novel HER-2 targeting agents (*C. Natoli, Chieti*)

B SERIE DI RELAZIONI SU TEMA PREORDINATO

Razionale

Breast cancer represents one of the most serious problems of oncology, being the leading cause of death of women in many countries. The present course will consolidate and integrate the varied aspects of the multidisciplinary care of breast cancer of main interest to surgeons, radiotherapists, medical oncologists, endocrinologists and cell biologists working in this field.

Particular attention will be given to the diagnosis and management of early and locally advanced breast cancer, focusing on new neoadjuvant approaches and on the issues related to nipple sparing/skin sparing mastectomy as well as radiation therapy and breast reconstruction.

A very interesting session of the course will cover the current controversies in the treatment of ductal carcinoma in situ, where still no consensus has been reached on optimal management, and questions related to the multidisciplinary treatment of very young and very old women with a breast cancer diagnosis.

Specific focus will be devoted to the current status and advances in management of hormone responsive, HER2 positive breast cancer and triple negative disease in the adjuvant as well as in the advanced setting.

The meeting beyond providing breast radiologists, radiotherapists, medical oncologists, surgeons, and fellows with an exhaustive overview on the various aspects (biological, molecular and therapeutic) linked to breast cancer management, will also give the opportunity to discuss controversial aspects with recognized experts in the field.